100% of evaluable participants at Month 6 achieved target absolute neutrophil count (ANC) increase with once-daily, oral mavorixafor +/- stable-dose G-CSF as of the interim analysis data cut-off date ...
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will host...
Merakris Therapeutics announced today that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.
X4 enters commercial fold with FDA approval of rare disease drug Xolremdi
PITTSBURGH, April 29, 2024 /PRNewswire/ -- PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, today announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI™ (mavorixafor), recently approved by the U.S. Food and Drug Administration (FDA) and the first FDA-approved therapy specifically indicated for use in patients 12 years of age and older with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome.
XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare...
Launch preparations underway in anticipation of possible U.S. approval of mavorixafor for WHIM syndrome; U.S. PDUFA target action date set for April 30, 2024 Additional Phase 2 clinical data and...
X4 Pharma Announces Presentation of Data from Mavorixafor Phase 2 Trial
X4 Pharmaceuticals Announces FDA Acceptance with Priority Review for Mavorixafor
Oral presentation further details positive data from mavorixafor Phase 1b clinical trial in people with chronic idiopathic, cyclic, or congenital neutropenia Medical claims research defines an...